Argonaut strategic partner, KBI Biopharma achieves Fill-Finish CDMO of the Year and Best in Class for Cultural Fit in the Small/Mid-Sized CDMO Biologic Categories
We congratulate our strategic partner, KBI Biopharma on their 2026 awards! Argonaut is proud to be KBI’s chosen fill-finish partner and to support their vision in drug development and biologics manufacturing.
As ecosystem partners, we provide an end-to-end solution for clients, especially those wanting faster program acceleration with minimal risks. Our teamwork begins with early-stage coordination and optimizes the transition from drug substance to fill-finish. KBI and Argonaut have not only aligned our quality systems, we coordinate schedules, share governance, provide open data exchanges, utilize a single point for project management and have mutual program goals. With partnership governance built for open data sharing, we avoid surprises during the drug product transfer.
“There’s full sharing upstream and downstream from the drug substance to the drug product team.” — Peter Carbone, COO at KBI Biopharma
Importantly, we have completed mutual audits of each other’s facilities and quality systems so compliance gaps are closed before programs start.
This partnership is built for sponsor and program managers who want a streamlined, smooth path without managing the handoffs themselves. KBI covers the drug substance development and manufacturing scope. Argonaut covers aseptic fill finish. Together we work as an extension of the sponsors CMC and quality team.
“We’ve aligned the quality systems to ensure that we can move with speed without compromising quality.” — Steve Folio VP Quality of Regulatory Affairs at Argonaut
Again, congratulations to the KBI BioPharma team!
If you want to know more about the Argonaut-KBI strategic initiative for drug substance to drug products, contact us.
